Under construction – not a live service
Sign in
Taking people in EgyptNo phase

Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis

Key facts

Where
Tanta, EgyptSee the site

Where in Egypt

  • Tanta universityTanta, EgyptContact: Mohammed S Elsharkawy, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Tanta University
Trial code
NCT07666347
Record updated
25 June 2026
Original description
This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.Read full original descriptionShow less

This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.

Inclusion: Age ≥ 50 years; Both genders; Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis; Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.

Exclusion: History of intra-articular injection within the last 6 months,; History of surgery on the knee joint or major trauma to the lower limb causing fracture; Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout; Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection; Hypersensitivity to Botulinum toxin or hyaluronic acid; Body mass index (BMI) more than 40 kg/m2; Diabetic patient.

ClinicalTrials.gov NCT07666347